London close: Stocks higher despite weaker retail sales data
17th Nov 2023 15:20
(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.
Read moreAstraZeneca gets US approval for breast cancer treatment
17th Nov 2023 07:16
(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.
Read moreAstraZeneca's latest lung cancer trial fails its primary endpoint
14th Nov 2023 09:22
(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Read moreLondon close: Stocks gain as investors await Powell speech
9th Nov 2023 15:02
(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.
Read moreAstraZeneca hikes guidance after strong third quarter
9th Nov 2023 07:18
(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.
Read moreAstraZeneca invests $220m in French gene-editing group Cellectis
1st Nov 2023 07:33
(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.
Read moreAstraZeneca agrees to settle most Nexium, Prilosec claims
3rd Oct 2023 07:24
(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.
Read moreAstraZeneca reports positive findings from breast cancer threatment trial
22nd Sep 2023 07:27
(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.
Read moreAstraZeneca working with FDA on finer details of Ultomiris treatment
6th Sep 2023 07:45
(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).
Read moreAstraZeneca posts strong first half despite Covid drug weakness
28th Jul 2023 07:04
(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.
Read moreAstraZeneca, Sanofi infant respiratory treatment gets US approval
18th Jul 2023 08:10
(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.
Read moreAstraZeneca reveals mixed interim findings in lung cancer trial
3rd Jul 2023 07:57
(Sharecast News) - AstraZeneca announced on Monday that datopotamab deruxtecan, or 'Dato-DXd', has shown promising results in a trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received at least one therapy.
Read moreAstraZeneca planning spinoff of China business - report
19th Jun 2023 09:28
(Sharecast News) - AstraZeneca has reportedly drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions.
Read moreAstraZeneca gets new FDA RSV approval, partners with Quell
9th Jun 2023 10:09
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) had unanimously voted in favour of 'nirsevimab' as a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.
Read moreAstraZeneca gets another US approval for Lynparza
1st Jun 2023 07:40
(Sharecast News) - AstraZeneca has received approval in the United States for the drug combination of 'Lynparza', or olaparib, with abiraterone and prednisone or prednisolone for the treatment of adult patients suffering from metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious BRCA mutations, it announced on Thursday.
Read more